A Study of a Novel Precision Medicine Approach for Obesity

Description

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

Conditions

Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.

A Novel Precision Medicine Approach for Obesity: a Randomized, Multi-Center Trial

A Study of a Novel Precision Medicine Approach for Obesity

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Jacksonville

Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Weight changes greater than 3% in the previous 3 months
  • * History of bariatric surgery including lap band and bariatric endoscopy
  • * Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia) and Columbia Suicide Severity Rating Scale (C-SSRS). If such a dysfunction is identified by an anxiety or depression score \>11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up. Any suicidal ideation of type 4 or 5, any suicide attempt during the patient's lifetime, or any suicidal behavior in the last month.
  • * Current use of anti-obesity medications or GLP1R agonists for Type 2 Diabetes
  • * Any contraindication to FDA-approved GLP1R agonists
  • * Positive score on the AUDIT-C questionnaire and any condition that limits their participation in the study
  • * A person who is pregnant or wanting to become pregnant
  • * Principal Investigator Discretion

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Andres Acosta, MD, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2028-11